{"id":"NCT02083380","sponsor":"Medicines for Malaria Venture","briefTitle":"Phase II Efficacy Study of Artefenomel & Piperaquine in Adults & Children With P. Falciparum Malaria.","officialTitle":"Randomised Phase IIb Study of Efficacy, Safety, Tolerability & Pharmacokinetics of a Single Dose Regimen of Artefenomel (OZ439) in Loose Combination With Piperaquine in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria.","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2014-07","primaryCompletion":"2015-10","completion":"2015-11","firstPosted":"2014-03-11","resultsPosted":"2017-01-30","lastUpdate":"2017-03-10"},"enrollment":448,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Uncomplicated Plasmodium Falciparum Malaria"],"interventions":[{"type":"DRUG","name":"Artefenomel 800mg: piperaquine 640mg","otherNames":["OZ439 ; PQP"]},{"type":"DRUG","name":"Artefenomel 800mg: piperaquine 960mg","otherNames":["OZ439 ; PQP"]},{"type":"DRUG","name":"Artefenomel 800mg: piperaquine 1440mg","otherNames":["OZ439 ; PQP"]}],"arms":[{"label":"A) Artefenomel 800mg: piperaquine 640mg","type":"EXPERIMENTAL"},{"label":"B) Artefenomel 800mg: piperaquine 960mg","type":"EXPERIMENTAL"},{"label":"C) Artefenomel 800mg: piperaquine 1440mg","type":"EXPERIMENTAL"}],"summary":"A randomised, double-blind single-dose study to determine the efficacy, safety, tolerability and pharmacokinetics of OZ439 (artefenomel) in combination with piperaquine (PQP) in patients \\> 0.5 years and \\<= 70 years of age with uncomplicated Plasmodium falciparum malaria in Africa and Asia (Vietnam).\n\nInterim analyses for futility were planned. Adults and children will be included through progressive step-down in age following safety review by an independent safety monitoring board (ISMB).\n\nIf the study were to meets its efficacy objectives, this will inform dose setting for Phase III studies.","primaryOutcome":{"measure":"PCR-adjusted ACPR at Day 28 in the PP Population (All Patients)","timeFrame":"Day 28","effectByArm":[{"arm":"A) Artefenomel 800mg: Piperaquine 640mg","deltaMin":70.8,"sd":null},{"arm":"B) Artefenomel 800mg: Piperaquine 960mg","deltaMin":68.4,"sd":null},{"arm":"C) Artefenomel 800mg: Piperaquine 1440mg","deltaMin":78.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":9,"countries":["Benin","Burkina Faso","Democratic Republic of the Congo","Gabon","Mozambique","Uganda","Vietnam"]},"refs":{"pmids":["30967148","28988541"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":146},"commonTop":["malaria","Electrocardiumgram QT prolonged","Diarrhoea","Vomiting","Neutrophil count decreased"]}}